A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 6-Week Clinical Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) at 320 or 640 mcg/Day in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 6-Week Clinical Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) at 320 or 640 mcg/Day in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Mar 2018

At a glance

  • Drugs Beclometasone (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Sponsors Teva Branded Pharmaceutical Products R&D

    • Most Recent Events

    • 05 Mar 2018 Results (n=425) of analysis assessing effect of Beclomethasone Dipropionate on patient reported outcomes and quality of life presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 05 Mar 2018 Results of post hoc analysis (n=425) evaluating improvement of lung function with beclomethasone dipropionate (BDP) via a new, breath-actuated inhaler presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 24 May 2017 Results assessing relationship between two methods of measuring forced expiratory volume in 1 second (handheld and clinic-based spirometry measurements), presented at the 113th International Conference of the American Thoracic Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top